Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock Rating Reaffirmed by JMP Securities

Deciphera Pharmaceuticals (NASDAQ:DCPH)‘s stock had its “market perform” rating reissued by JMP Securities in a research report issued to clients and investors on Tuesday, Benzinga reports.

DCPH has been the topic of a number of other reports. Stifel Nicolaus boosted their target price on shares of Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday. Barclays raised shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $9.00 to $26.00 in a report on Tuesday. Jonestrading reaffirmed a “hold” rating and issued a $25.60 price target on shares of Deciphera Pharmaceuticals in a report on Monday. Finally, JPMorgan Chase & Co. increased their target price on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $24.17.

Deciphera Pharmaceuticals Stock Performance

Deciphera Pharmaceuticals stock traded up $0.05 during trading on Tuesday, reaching $25.33. The company had a trading volume of 2,096,393 shares, compared to its average volume of 1,143,882. Deciphera Pharmaceuticals has a 12-month low of $9.90 and a 12-month high of $25.40. The stock’s 50 day moving average price is $15.78 and its two-hundred day moving average price is $14.45. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -11.06 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. The firm had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. Deciphera Pharmaceuticals’s revenue was up 32.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.60) earnings per share. As a group, research analysts expect that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

Several large investors have recently bought and sold shares of DCPH. Frazier Life Sciences Management L.P. increased its stake in Deciphera Pharmaceuticals by 176.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock valued at $16,482,000 after buying an additional 651,800 shares during the period. Armistice Capital LLC increased its stake in Deciphera Pharmaceuticals by 12.7% during the 4th quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $83,876,000 after buying an additional 588,000 shares during the period. Goldman Sachs Group Inc. increased its stake in Deciphera Pharmaceuticals by 14.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after buying an additional 290,968 shares during the period. Deerfield Management Company L.P. Series C increased its stake in Deciphera Pharmaceuticals by 2.8% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 6,897,606 shares of the company’s stock valued at $87,738,000 after buying an additional 190,580 shares during the period. Finally, Panagora Asset Management Inc. increased its stake in Deciphera Pharmaceuticals by 157.1% during the 4th quarter. Panagora Asset Management Inc. now owns 235,845 shares of the company’s stock valued at $3,804,000 after buying an additional 144,097 shares during the period. Institutional investors and hedge funds own 70.96% of the company’s stock.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.